VU University Medical Center, Department of Rheumatology, 1081 HV Amsterdam, The Netherlands.
Clin Exp Rheumatol. 2011 Sep-Oct;29(5 Suppl 68):S93-8. Epub 2011 Oct 21.
Glucocorticoid-induced osteoporosis is one of the most important side-effects of glucocorticoid use, leading to an increased fracture risk. In this review, recent advances in the understanding of the mechanisms of glucocorticoid-induced osteoporosis are summarised. Methods to identify persons at risk for fractures are discussed, as well as the new ACR recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis (2010). Different treatment options are summarised considering the pathogenesis of glucocorticoid-induced osteoporosis. Improved insights into pathogenesis might result in development of new treatment possibilities.
糖皮质激素诱导的骨质疏松症是糖皮质激素应用的最重要的副作用之一,导致骨折风险增加。在这篇综述中,总结了糖皮质激素诱导的骨质疏松症机制的最新研究进展。讨论了识别骨折风险人群的方法,以及 ACR 关于预防和治疗糖皮质激素诱导的骨质疏松症(2010 年)的新建议。根据糖皮质激素诱导的骨质疏松症的发病机制,总结了不同的治疗选择。对发病机制的深入了解可能会导致新的治疗方法的开发。